Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma

Best Pract Res Clin Haematol. 2023 Mar;36(1):101442. doi: 10.1016/j.beha.2023.101442. Epub 2023 Feb 2.

Abstract

The prognosis is dismal (2-year overall survival less than 25%) for childhood, adolescent, and young adult (CAYA) with relapsed and/or refractory (R/R) non-Hodgkin lymphoma (NHL). Novel targeted therapies are desperately needed for this poor-risk population. CD19, CD20, CD22, CD79a, CD38, CD30, LMP1 and LMP2 are attractive targets for immunotherapy in CAYA patients with R/R NHL. Novel anti-CD20 monoclonal antibodies, anti-CD38 monoclonal antibody, antibody drug conjugates and T and natural killer (NK)-cell bispecific and trispecific engagers are being investigated in the R/R setting and are changing the landscape of NHL therapy. A variety of cellular immunotherapies such as viral activated cytotoxic T-lymphocyte, chimeric antigen receptor (CAR) T-cells, NK and CAR NK-cells have been investigated and provide alternative options for CAYA patients with R/R NHL. Here, we provide an update and clinical practice guidance of utilizing these cellular and humoral immunotherapies in CAYA patients with R/R NHL.

Keywords: Anti-CD20 antibody; Anti-CD38 antibody; Antibody-drug conjugate; Bispecific and trispecific engagers; CAR NK; CAR T, viral activated cytotoxic T-lymphocyte; IL-15; Immunotherapy; Relapsed and/or refractory non-Hodgkin lymphoma.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antigens, CD19
  • Antineoplastic Agents* / therapeutic use
  • Child
  • Humans
  • Immunoconjugates* / therapeutic use
  • Immunotherapy
  • Immunotherapy, Adoptive
  • Killer Cells, Natural / pathology
  • Lymphoma, Non-Hodgkin* / drug therapy
  • Young Adult

Substances

  • Antineoplastic Agents
  • Immunoconjugates
  • Antigens, CD19